Cargando…

Is critical care ready for an economic surrogate endpoint?

Intensive care is expensive, and thus a body of research has focused on strategies to reduce its costs. However, efforts to reduce the total cost of intensive care have met with limited success, partly because of the challenges of calculating how much a day in the ICU actually costs. We discuss thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilcox, M Elizabeth, Rubenfeld, Gordon D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464123/
https://www.ncbi.nlm.nih.gov/pubmed/26067467
http://dx.doi.org/10.1186/s13054-015-0947-0
_version_ 1782375895375282176
author Wilcox, M Elizabeth
Rubenfeld, Gordon D
author_facet Wilcox, M Elizabeth
Rubenfeld, Gordon D
author_sort Wilcox, M Elizabeth
collection PubMed
description Intensive care is expensive, and thus a body of research has focused on strategies to reduce its costs. However, efforts to reduce the total cost of intensive care have met with limited success, partly because of the challenges of calculating how much a day in the ICU actually costs. We discuss these challenges and introduce the concept of total cost savings as an outcome of critical care trials, assuming statistically negative effects on mortality and quality of life.
format Online
Article
Text
id pubmed-4464123
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44641232015-06-14 Is critical care ready for an economic surrogate endpoint? Wilcox, M Elizabeth Rubenfeld, Gordon D Crit Care Commentary Intensive care is expensive, and thus a body of research has focused on strategies to reduce its costs. However, efforts to reduce the total cost of intensive care have met with limited success, partly because of the challenges of calculating how much a day in the ICU actually costs. We discuss these challenges and introduce the concept of total cost savings as an outcome of critical care trials, assuming statistically negative effects on mortality and quality of life. BioMed Central 2015-06-11 2015 /pmc/articles/PMC4464123/ /pubmed/26067467 http://dx.doi.org/10.1186/s13054-015-0947-0 Text en © Wilcox and Rubenfeld. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Wilcox, M Elizabeth
Rubenfeld, Gordon D
Is critical care ready for an economic surrogate endpoint?
title Is critical care ready for an economic surrogate endpoint?
title_full Is critical care ready for an economic surrogate endpoint?
title_fullStr Is critical care ready for an economic surrogate endpoint?
title_full_unstemmed Is critical care ready for an economic surrogate endpoint?
title_short Is critical care ready for an economic surrogate endpoint?
title_sort is critical care ready for an economic surrogate endpoint?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464123/
https://www.ncbi.nlm.nih.gov/pubmed/26067467
http://dx.doi.org/10.1186/s13054-015-0947-0
work_keys_str_mv AT wilcoxmelizabeth iscriticalcarereadyforaneconomicsurrogateendpoint
AT rubenfeldgordond iscriticalcarereadyforaneconomicsurrogateendpoint